Literature DB >> 23242702

Attacking the HIV reservoir from the immune and viral perspective.

Marta Massanella1, Javier Martinez-Picado, Julià Blanco.   

Abstract

Upon HIV infection, a subset of latently infected cells carrying transcriptionally inactive integrated proviral DNA (the HIV-1 reservoir) is rapidly established. These cells are the main force behind HIV persistence under highly active antiretroviral therapy (HAART), which only impacts on actively replicating viruses and it is therefore unable to eradicate the infection. However, the case of Timothy Brown, also known as the Berlin patient, demonstrates that eradication is possible, and recent data support the idea that latency may be reverted in vivo, suggesting that it is possible to perturb the HIV-1 reservoir. This may be achieved by implementing both pharmacological and immunological strategies to reactivate HIV-1 from latently infected cells. Nevertheless, reactivation might not be sufficient to eradicate the virus. Reinforcing HIV-1-specific immune responses and blocking potential new events of viral replication will probably help reaching the final goal of eradication or the alternative objective of a functional cure for HIV-1.

Entities:  

Mesh:

Year:  2013        PMID: 23242702     DOI: 10.1007/s11904-012-0150-8

Source DB:  PubMed          Journal:  Curr HIV/AIDS Rep        ISSN: 1548-3568            Impact factor:   5.071


  102 in total

1.  Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells.

Authors:  Janet D Siliciano; Joleen Kajdas; Diana Finzi; Thomas C Quinn; Karen Chadwick; Joseph B Margolick; Colin Kovacs; Stephen J Gange; Robert F Siliciano
Journal:  Nat Med       Date:  2003-05-18       Impact factor: 53.440

2.  Persistent low-level viremia in HIV-1 elite controllers and relationship to immunologic parameters.

Authors:  Florencia Pereyra; Sarah Palmer; Toshiyuki Miura; Brian L Block; Ann Wiegand; Alissa C Rothchild; Brett Baker; Rachel Rosenberg; Emily Cutrell; Michael S Seaman; John M Coffin; Bruce D Walker
Journal:  J Infect Dis       Date:  2009-09-15       Impact factor: 5.226

3.  Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy.

Authors:  T W Chun; L Stuyver; S B Mizell; L A Ehler; J A Mican; M Baseler; A L Lloyd; M A Nowak; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

4.  Cellular reservoirs of HIV-1 in the central nervous system of infected individuals: identification by the combination of in situ polymerase chain reaction and immunohistochemistry.

Authors:  O Bagasra; E Lavi; L Bobroski; K Khalili; J P Pestaner; R Tawadros; R J Pomerantz
Journal:  AIDS       Date:  1996-06       Impact factor: 4.177

5.  Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study.

Authors:  Josep M Llibre; Maria J Buzón; Marta Massanella; Anna Esteve; Viktor Dahl; Maria C Puertas; Pere Domingo; Josep M Gatell; Maria Larrouse; Mar Gutierrez; Sarah Palmer; Mario Stevenson; Julià Blanco; Javier Martinez-Picado; Bonaventura Clotet
Journal:  Antivir Ther       Date:  2011-09-28

6.  HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects.

Authors:  Maria J Buzón; Marta Massanella; Josep M Llibre; Anna Esteve; Viktor Dahl; Maria C Puertas; Josep M Gatell; Pere Domingo; Roger Paredes; Mark Sharkey; Sarah Palmer; Mario Stevenson; Bonaventura Clotet; Julià Blanco; Javier Martinez-Picado
Journal:  Nat Med       Date:  2010-03-14       Impact factor: 53.440

7.  Interleukin-21 administration to rhesus macaques chronically infected with simian immunodeficiency virus increases cytotoxic effector molecules in T cells and NK cells and enhances B cell function without increasing immune activation or viral replication.

Authors:  Suresh Pallikkuth; Kenneth Rogers; Francois Villinger; Melvin Dosterii; Monica Vaccari; Genoveffa Franchini; Rajendra Pahwa; Savita Pahwa
Journal:  Vaccine       Date:  2011-10-11       Impact factor: 3.641

8.  Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation.

Authors:  Sifei Xing; Cynthia K Bullen; Neeta S Shroff; Liang Shan; Hung-Chih Yang; Jordyn L Manucci; Shridhar Bhat; Hao Zhang; Joseph B Margolick; Thomas C Quinn; David M Margolis; Janet D Siliciano; Robert F Siliciano
Journal:  J Virol       Date:  2011-04-06       Impact factor: 5.103

9.  Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment.

Authors:  Yves Levy; Christine Lacabaratz; Laurence Weiss; Jean-Paul Viard; Cecile Goujard; Jean-Daniel Lelièvre; François Boué; Jean-Michel Molina; Christine Rouzioux; Véronique Avettand-Fénoêl; Thérèse Croughs; Stéphanie Beq; Rodolphe Thiébaut; Geneviève Chêne; Michel Morre; Jean-François Delfraissy
Journal:  J Clin Invest       Date:  2009-03-16       Impact factor: 14.808

10.  HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation.

Authors:  Nicolas Chomont; Mohamed El-Far; Petronela Ancuta; Lydie Trautmann; Francesco A Procopio; Bader Yassine-Diab; Geneviève Boucher; Mohamed-Rachid Boulassel; Georges Ghattas; Jason M Brenchley; Timothy W Schacker; Brenna J Hill; Daniel C Douek; Jean-Pierre Routy; Elias K Haddad; Rafick-Pierre Sékaly
Journal:  Nat Med       Date:  2009-06-21       Impact factor: 53.440

View more
  6 in total

Review 1.  Targeting HIV latency: resting memory T cells, hematopoietic progenitor cells and future directions.

Authors:  Nadia T Sebastian; Kathleen L Collins
Journal:  Expert Rev Anti Infect Ther       Date:  2014-09-04       Impact factor: 5.091

2.  Role of P-glycoprotein in the distribution of the HIV protease inhibitor atazanavir in the brain and male genital tract.

Authors:  Kevin R Robillard; Gary N Y Chan; Guijin Zhang; Charles la Porte; William Cameron; Reina Bendayan
Journal:  Antimicrob Agents Chemother       Date:  2013-12-30       Impact factor: 5.191

3.  HIV-1 specific antibody titers and neutralization among chronically infected patients on long-term suppressive antiretroviral therapy (ART): a cross-sectional study.

Authors:  Johannes S Gach; Chad J Achenbach; Veronika Chromikova; Baiba Berzins; Nina Lambert; Gary Landucci; Donald N Forthal; Christine Katlama; Barbara H Jung; Robert L Murphy
Journal:  PLoS One       Date:  2014-01-15       Impact factor: 3.752

4.  Different plasma markers of inflammation are influenced by immune recovery and cART composition or intensification in treated HIV infected individuals.

Authors:  Marta Massanella; Dan Ouchi; Silvia Marfil; Josep M Llibre; Maria C Puertas; María J Buzón; Douglas D Richman; Elisa Orna; Mario Stevenson; Josep M Gatell; Pere Domingo; Eugènia Negredo; Javier Martinez-Picado; Bonaventura Clotet; Julià Blanco
Journal:  PLoS One       Date:  2014-12-02       Impact factor: 3.240

Review 5.  Antibodies and Antibody Derivatives: New Partners in HIV Eradication Strategies.

Authors:  Jorge Carrillo; Bonaventura Clotet; Julià Blanco
Journal:  Front Immunol       Date:  2018-10-23       Impact factor: 7.561

Review 6.  HIV-1 Trans Infection of CD4(+) T Cells by Professional Antigen Presenting Cells.

Authors:  Charles R Rinaldo
Journal:  Scientifica (Cairo)       Date:  2013-05-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.